VERA Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a ful…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 2 ‘Strong Buy’ Stocks Where a Short Squeeze Could Be Brewing Should you short stocks right now? That’s a good question, and it’s one with no clear answer. There’s still a bullish feeling in the air, but volatility is rising, and there’s no guarantee the bulls will keep running. In a market like this, it can be tempting to bet against stocks. Shorting a stock can be a fast track to profits, but it’s also a fast track to risk. A short seller borrows shares and sells them, hoping to buy them back later at a lower price. If the stock rises instead, the short | ||
 Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III Endpoints Vera Therapeutics (NasdaqGM: VERA) reported that TRUTAKNA met all prespecified endpoints in the final Phase III ORIGIN 3 trial for IgA nephropathy. The company said the study showed prevention of disease progression and stabilization of kidney function alongside a favorable safety profile. Management plans to seek full FDA approval for TRUTAKNA later in 2026 through a supplemental biologics license application. The confirmation of TRUTAKNA's Phase III success sits against a wider backdrop of... | ||
 Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%. | ||
 Vera Reverses Its Major Chart Upset As Vertex Rivalry Deepens — What Happened? Vera stock reversed course Tuesday despite positive results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex. | ||
 Vera set up for full approval for Trutakna in IgAN with Phase III win Vera’s Trutakna was granted FDA accelerated approval in IgAN based on 36-week data. | ||
 Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna. | ||
Top Midday Stories: Waystar Reportedly Mulling Potential Sale; Intel-Backed Altera Says Parent Company Files Confidentially for IPO All three major US stock indexes were down in late-morning trading Tuesday, as Treasury yields conti | ||
 Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints Vera Therapeutics (NASDAQ:VERA) shares rose 13% on Tuesday after the company reported that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of its ORIGIN 3 trial in adults with primary IgA nephropathy. The company said the results showed that TRUTAKNA stabilised estimated glomerular filtration rate, or eGFR, and reduced kidney disease progression through two years in patients considered at risk of disease progression. | ||
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Traders Prepare for Fed Meeting The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2%, and the actively t | ||
Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD | ||
 VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4 Vera Therapeutics stated that Trutakna's commercial launch generated more than 350 patient start forms in the first 10 weeks. | ||